ACUTE PROMYELOCYTIC LEUKEMIA T

The APL T(15;17) Test detects the translocation between chromosomes 15 and 17, resulting in the PML-RARA fusion gene, which is characteristic of acute promyelocytic leukemia (APL).

This test is recommended for:

• Patients with suspected APL based on clinical and hematological findings.
  
  
• Individuals requiring confirmation of APL diagnosis before initiating targeted therapy.
  
  
• Monitoring response to therapy in diagnosed APL patients.
  
  

A blood or bone marrow sample is analyzed using fluorescence in situ hybridization (FISH), PCR, or cytogenetic analysis to detect the PML-RARA fusion.

• Positive Result: Confirms the presence of the PML-RARA fusion gene, diagnosing APL.
  
  
• Negative Result: Suggests the absence of APL but further tests may be required for other leukemia types.
  
  

Identifying APL ensures timely administration of all-trans retinoic acid (ATRA) and arsenic trioxide therapy, which can significantly improve outcomes.